Skip Ribbon Commands
Skip to main content
Clin Asst Prof Lee Jie Xin Joycelyn

Clin Asst Prof Lee Jie Xin Joycelyn

MBBS, MRCP (UK), M Med (Internal Medicine)


National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Interest: Gastrointestinal, Upper Gastrointestinal

Conditions Treated by this Doctor:
Biliary Tract Cancer, Colorectal Cancer, Liver Cancer, Oesophageal Cancer, Oesophageal Cancer, Pancreatic Cancer, Stomach Cancer.

Clinical Appointments

  • Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Asst Professor at Duke-NUS Medical School
  • Posting Lead, Adjunct Faculty, LKC School of Medicine, NTU
  • Clinical Lecturer, Yong Loo Lin School of Medicine, NUS


Dr Lee is a medical oncologist in the Department of Gastrointestinal Oncology, Division of Medical Oncology at National Cancer Centre Singapore. She sees patients and conducts clinical research in the field of gastrointestinal oncology, with an interest in hepatopancreatobiliary cancers, immuno-oncology and supportive care. She participates in postgraduate and undergraduate medical teaching.


  • FAMS (Medical Oncology) 2017
  • MRCP (UK) 2013
  • M.Med (Int Med) 2013
  • MBBS (Singapore) 2011

Professional Appointments and Committee Memberships

  • SSO-CIC Executive Committee 2021 – present
  • Member of SSO, ASCO, ESMO since 2014


  • Singhealth Quality Service Award 2018, 2019
  • Young Educator Award 2012

Research Interests

  • Hepatopancreatobiliary cancers
  • Immuno-oncology
  • Supportive care


  • Radioembolisation with Y90-resin microspheres followed by nivolumab for  advanced hepatocellular carcinoma (CA 209-678): a single-arm single-centre phase 2 trial. Tai D, Loke K .. Lee J .. Choo SP. Lancet Gastro Hepatol 2021 Dec; 6(12): 1025 – 1035.
  • Impact of immune-related adverse events on efficacy of Immune Checkpoint Inhibitors in patients with advanced hepatocellular carcinoma. Ng KYY, Tan SH .. Lee JJX. Liver Cancer 2021.
  • Locoregional therapy in hepatocellular carcinoma: when to start, when to stop and when to revisit. Lee JJX, Tai D, Choo SP. ESMO Open 2021 June; 6(3):100.129
  • Clinical outcomes with Multikinase inhibitors after Progression on First-line Atezolizumab plus Bevacizumab in Patients with advanced HCC: a Multinational, Multicentre Retrospective study. Yoo C, Kim JH .. Lee J.. et al. Liver Cancer 2021 Apr; 10(2): 107 - 114

Research Trials

  • Immuno-Oncology Toxicity Database (Principal Investigator)